A new study found no survival advantage with filgrastim-mobilized peripheral blood stem cells compared to bone marrow transplants from unrelated donors. PBSC transplants are associated with higher rates of chronic graft-versus-host disease (GVHD), particularly in patients receiving unrelated donor transplants.
Researchers have discovered that administering aspirin after standard therapy for venous thromboembolism (VTE) may prevent the recurrence of potentially deadly blood clots. The WARFASA study found that low-dose aspirin reduced VTE recurrence by 6.6% compared to placebo, with a similar incidence of major and non-major bleeding.
A Phase III clinical trial found that adding gemtuzumab ozogamicin to standard chemotherapy improved event-free and overall survival in newly-diagnosed acute myeloid leukemia patients aged 50-70. The treatment also reduced toxicity while providing therapeutic benefits.
A study found that children with sickle cell anemia are at risk for silent cerebral infarcts due to low hemoglobin levels, high systolic blood pressure, and male gender. The risk of silent strokes increases by age six, with over 25% of children suffering a stroke by then.
For the first time, researchers have successfully injected cultured red blood cells (cRBCs) created from human hematopoietic stem cells (HSCs) into a human donor. The cRBCs were capable of progressing through the full maturation process and demonstrated survival rates comparable to conventional native red blood cells.
Patients with clinically diagnosed superficial vein thrombosis are four to six times more likely to develop venous thromboembolism, a dangerous and often life-threatening condition. Studies have shown that patients with
Researchers investigated potential effects of G-CSF on chromosomes in healthy PBSC donors and found no replication asynchrony or atypical abnormalities. The study concludes that G-CSF mobilization process is safe for healthy stem cell donors, supporting its use in transplants.
Researchers developed an effective gene therapy technique using induced pluripotent stem cells to correct chronic granulomatous disease in cell culture. The corrected neutrophils produced normal levels of hydrogen peroxide, potentially offering a cure for the rare disorder.
A pilot project aims to improve the accuracy of acute myeloid leukemia (AML) diagnoses in Mexico by standardizing cytogenetic testing. Four Mexican laboratories will participate in the project, which includes a two-year program with oversight from ASH, AMEH, and NCI experts.
A study published in Blood reveals that imatinib treatment has no significant impact on the outcome of chronic myeloid leukemia (CML) patients aged 65 and older. The research found that complete hematologic response rates, cytogenetic response rates, and overall survival rates were similar between younger and older patients treated wit...
A study published in Blood reveals a close relationship between pulmonary arterial hypertension and myeloid abnormalities in the bone marrow. The researchers found that blood progenitor cells are increased in patients with PAH, suggesting an abnormal feedback loop connecting blood and lung cell behavior.
Researchers found that early infusion of donor T cells prevented GVHD in 26 patients who achieved full-donor engraftment, with no chronic GVHD development. The study also showed improved immune system recovery and reduced CMV reactivation.
A study published in Blood demonstrates that newborn screening and early diagnosis of Severe Combined Immunodeficiency (SCID) can improve survival rates. Babies diagnosed at birth and receiving a hematopoietic stem cell transplant have significantly reduced infections and improved survival outcomes.
The American Society of Hematology awards $100,000 to fellows and $150,000 to junior faculty for a two- to three-year research period. The 2011 Scholar Award recipients include Basic Research Fellow Omar I. Abdel-Wahab, MD, and Clinical/Translational Research Fellow Samantha M. Jaglowski, MD.
Studies reveal that stem cell transplantation is safe and effective in treating various hematologic malignancies, with no significant increase in overall cancer risk. Researchers found a promising new treatment to prevent chronic graft-versus-host disease, a serious complication of stem cell transplantation.
Researchers present promising new treatment options for advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early Hodgkin disease. The study shows that upfront rituximab therapy can significantly prolong the time until a patient may require chemotherapy.
Researchers have made significant strides in understanding the optimal use of BCR-ABL inhibitors for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). A new gene target has also been identified, showing a long-term survival advantage for patients treated with imatinib earlier in the treatment protocol.
Researchers investigate genetic predictors of stroke in pediatric sickle cell disease patients, validating biomarkers and identifying new risk factors. Additionally, a potential breakthrough may inhibit malaria transmission, offering hope for controlling the disease.
Researchers found that apixaban was more effective than enoxaparin in preventing major venous thromboembolism without increasing bleeding risk. This innovative treatment has improved methods for patients undergoing hip or knee replacement surgery, and may also be beneficial for cancer patients with VTE.
The updated guideline advises physicians to discuss individual risks and benefits of ESAs with cancer patients, recommending cautious use due to associated risks of thromboembolism and tumor progression. ESAs are still effective in reducing red blood cell transfusions, which can impact quality of life.
A new risk prediction model for venous thromboembolism (VTE) in cancer patients has been developed, incorporating two new biomarkers. The model improves the classification of patients into different risk categories, with a significant increase in accurate predictions of VTE development.
Chronic health conditions are widespread among stem cell transplant survivors, with 66% reporting at least one condition and 35% experiencing three or more. Chronic graft-versus-host disease also increases the risk of severe or life-threatening conditions.
A recent study published in Blood journal of American Society of Hematology found that cancer cells can contaminate ovarian tissue in women with leukemia, making fertility preservation methods unsafe. The study suggests that cancer cells from acute and chronic leukemias can be present in frozen-thawed ovarian tissue.
The American Society of Hematology (ASH) has developed recommendations for advancing regenerative medicine. The key focus areas include recognizing regenerative medicine as a priority at the National Institutes of Health (NIH), re-examining clinical trial methodologies, and improving communication between basic and clinical scientists.
For nearly three-quarters of elderly patients, intensive chemotherapy is associated with poor prognosis and low median survival time. Researchers identified several predictive factors for mortality rate, including age over 80, genetic abnormalities, and kidney function impairment.
The American Society of Hematology will honor six scientists with significant contributions to the understanding and treatment of hematologic diseases. Volker Diehl, Sanford Shattil, David T. Scadden, Leonard I. Zon, Barry S. Coller, and Joel S. Bennett will receive awards for their pioneering research in Hodgkin lymphoma, platelet cel...
A study found that more than 40% of patients with treatment-resistant CLL enjoyed long-term freedom from relapse after receiving allogeneic stem cell transplants. The transplants were associated with significant risks but offered a potential cure for this patient population.
Research finds that radiation therapy to lymph nodes in the chest increases cardiac hospitalization risk among patients with pre-existing heart disease. Patients treated with chemotherapy alone have lower cardiac complication rates, highlighting the need for post-treatment monitoring and intervention.
A Phase II clinical trial of eliglustat tartrate, an oral therapy, demonstrates significant improvements in spleen volume, hemoglobin level, and platelet count. The treatment also normalizes glucosylceramide plasma levels and improves bone mineral density.
The study found a strong association between the Human Development Index and rates of stem cell transplantation for acute myeloid leukemia patients. Countries with higher HDI scores had significantly better outcomes, including reduced risk of relapse and improved leukemia-free survival.
Researchers found evidence that fat tissue contains functional hematopoietic stem and progenitor cells, which can regenerate and develop into various cell types. The study suggests that adipose tissue may be a valuable alternative source of these cells, potentially replacing bone marrow transplantation in the future.
Recent studies on anticoagulants suggest that aspirin and heparin may not be effective in preventing unexplained, recurrent miscarriages. In contrast, a new study shows that dabigatran etexilate is as safe and effective as warfarin for treating venous thromboembolism.
Researchers have made significant breakthroughs in understanding the genetic basis of sickle cell disease, exploring the potential of activating fetal hemoglobin to reduce complications. A new study found that activating BCL11A could lead to increased production of healthy hemoglobin, providing a promising avenue for treatment.
A new study demonstrates advances in optimizing treatments and quality of life for patients with multiple myeloma. The research explores optimal induction therapies, advance care planning, and a potential new first-line therapy for non-Hodgkin lymphoma.
Researchers have developed a new protocol to improve the survival of patients with acute promyelocytic leukemia and chronic myeloid leukemia, particularly in developing countries. The study found a significant improvement in early mortality and long-term outcomes, with high rates of complete remission.
Researchers developed a new approach to prevent graft-versus-host disease and enhance immune recovery after haploidentical transplants. The study showed long-term protection from graft-versus-host disease in 25 of 26 patients, with improved immune system reconstitution.
The American Society of Hematology recognizes outstanding abstract presenters with the 2009 Merit Award, offering $500 honorariums to the best trainees in hemostasis and thrombosis. The winners include Kimberly Fan, Kyle Eash, Hélène Moniz, An De Weer, Suparna Nanua, MD, PhD, Jian Xu, PhD, and Rudy Fuentes.
The American Society of Hematology recognizes Stuart H. Orkin, MD, and Arthur W. Nienhuis, MD, for their significant contributions to mentoring in hematology. Drs. Orkin and Nienhuis will receive the Mentor Award for Basic Science and Clinical Investigation, respectively.
A new study demonstrates the effectiveness of immunotherapy using specialized white blood cells to prevent or treat EBV-lymphoma in patients who have received a hematopoietic stem cell transplant. The therapy achieved sustained complete remission in 85% of treated patients and long-term protection for up to nine years.
A new study shows that anemic patients with myelodysplastic syndromes (MDS) can gain long-term benefits from erythropoietin and a myeloid growth factor, with improved survival rates and overall quality of life compared to those receiving supportive care alone.
Research found that African Americans with HIV who have a genetic variation and low white blood cell count have slower disease progression rates. This study suggests a unique survival advantage for African Americans with HIV if they possess both a DARC variation and leukopenia.
The American Society of Hematology is honoring six scientists for their significant contributions to hematologic diseases, including the diagnosis and treatment of lymphomas and leukemia. The awards recognize pioneering research achievements and outstanding leadership in advancing the field of hematology.
A study of 678 pesticide users found a double risk of developing MGUS compared to the general population. The research suggests exposure to certain pesticides increases the risk of this abnormal blood condition, which requires lifelong monitoring as it can lead to multiple myeloma.
Scientists have successfully reprogrammed blood cells into cells that mimic embryonic stem cells, opening up new avenues for research and potential treatment of diseases. The discovery provides an accessible source of stem cells, which can be used to study various diseases and develop new therapies.
Scientists have discovered that amniotic fluid contains a new source of stem cells with potential therapeutic applications. These cells, known as AFKL cells, can generate all blood cell lineages in experiments and exhibit self-renewal capabilities, similar to other stem cells.
A new study suggests that green tea components may negate the effects of bortezomib (Velcade) in patients taking this medicine. The EGCG polyphenol in green tea bound to boronic acid-containing compounds like bortezomib cancels out their antitumor effects.
Researchers have found that preventive use of antithrombotic medication can reduce incidence of thromboembolic events in cancer patients. The PROTECHT Study shows a 47.2% reduction in risk, while also demonstrating safety with minimal major bleeding episodes.
Two studies examine the impact of cord blood, peripheral blood, and bone marrow on transplant success rates in adults with acute leukemia. The research reveals that mismatched cord blood transplants can be a suitable alternative to bone marrow or peripheral blood transplants.
The study presents a new combination therapy for previously untreated ITP, an investigational oral treatment for chronic ITP, and a low-dose platelet transfusion strategy. These approaches aim to minimize bleeding episodes in patients with platelet disorders.
Four studies showcase treatment advances in blood cancers, including improved progression-free survival for patients with relapsed or refractory chronic lymphocytic leukemia. A new tumor suppressor gene is also discovered in patients with myeloproliferative disorders.